Liquidia (NASDAQ:LQDA) Trading Up 2.3%

Shares of Liquidia Co. (NASDAQ:LQDA - Get Free Report) shot up 2.3% during trading on Tuesday . The stock traded as high as $15.37 and last traded at $15.27. 62,039 shares were traded during mid-day trading, a decline of 94% from the average session volume of 977,694 shares. The stock had previously closed at $14.92.

Wall Street Analysts Forecast Growth

Several research firms recently commented on LQDA. HC Wainwright upped their price target on shares of Liquidia from $16.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, March 14th. Needham & Company LLC reiterated a "buy" rating and set a $28.00 price objective on shares of Liquidia in a research note on Monday. LADENBURG THALM/SH SH increased their price objective on shares of Liquidia from $15.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, December 21st. Bank of America increased their price objective on shares of Liquidia from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Thursday, December 21st. Finally, Wedbush reiterated an "underperform" rating and set a $3.00 price objective on shares of Liquidia in a research note on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.00.

Liquidia Trading Up 3.1 %

The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -12.82 and a beta of 0.16. The stock's 50-day moving average price is $14.38 and its 200-day moving average price is $10.34.

Insider Transactions at Liquidia

In other news, General Counsel Russell Schundler sold 8,653 shares of the business's stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $15.82, for a total value of $136,890.46. Following the transaction, the general counsel now owns 488,087 shares in the company, valued at approximately $7,721,536.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, General Counsel Russell Schundler sold 8,653 shares of Liquidia stock in a transaction on Monday, March 18th. The shares were sold at an average price of $15.82, for a total value of $136,890.46. Following the completion of the sale, the general counsel now owns 488,087 shares in the company, valued at approximately $7,721,536.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Roger Jeffs sold 28,583 shares of the business's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $15.82, for a total transaction of $452,183.06. Following the sale, the chief executive officer now owns 835,345 shares of the company's stock, valued at approximately $13,215,157.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 54,605 shares of company stock worth $862,904. Company insiders own 31.60% of the company's stock.

Institutional Investors Weigh In On Liquidia

Institutional investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its position in shares of Liquidia by 9.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,342 shares of the company's stock worth $137,000 after purchasing an additional 989 shares during the last quarter. SkyView Investment Advisors LLC raised its holdings in Liquidia by 1.4% in the fourth quarter. SkyView Investment Advisors LLC now owns 111,571 shares of the company's stock worth $1,342,000 after purchasing an additional 1,571 shares in the last quarter. BNP Paribas Arbitrage SNC raised its holdings in Liquidia by 20.5% in the first quarter. BNP Paribas Arbitrage SNC now owns 9,993 shares of the company's stock worth $69,000 after purchasing an additional 1,702 shares in the last quarter. Chartwell Investment Partners LLC raised its holdings in Liquidia by 6.0% in the fourth quarter. Chartwell Investment Partners LLC now owns 31,024 shares of the company's stock worth $197,000 after purchasing an additional 1,769 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Liquidia by 7.1% during the fourth quarter. JPMorgan Chase & Co. now owns 27,923 shares of the company's stock valued at $178,000 after acquiring an additional 1,845 shares in the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).